何娟

【摘 要】目的：分析厄贝沙坦联合胺碘酮治疗慢性心力衰竭合并室性心律失常的临床疗效。方法：以慢性心力衰竭合并室性心律失常患者100例为研究对象，纳入时间为2016年2月-2018年12月，采用抽签法进行分组，分别为参照组与研究组，每组各50例，给予参照组胺碘酮治疗，给予研究组厄贝沙坦联合胺碘酮治疗。对比两组患者的治疗效果、心率变化、心功能与不良反应，使用统计学进行分析。结果：研究组治疗有效率高于参照组，P<0.05。研究组治疗后心率改善优于参照组，P<0.05。研究组治疗后左室射血分数、左室舒张末径均改善优于参照组，P<0.05。研究组不良反应与参照组比较，P>0.05。结论：对慢性心力衰竭合并室性心律失常患者实施厄贝沙坦联合胺碘酮治疗，有效提高治疗有效率，改善心功能，不良反应少，安全性高，治疗效果显著。

【关键词】厄贝沙坦;胺碘酮;慢性心力衰竭;室性心律失常

Abstract： .objective to analyze the clinical efficacy of irbesartan combined with amiodarone in the treatment of chronic heart failure with ventricular arrhythmia. Methods a total of100patients with chronic heart failure complicated with ventricular arrhythmia were selected as the study objects and included from February2016to December2018. They were divided into the reference group and the study group by lot.50patients in each group were treated with histamine iodarone as the reference group and irbersardine combined with amiodarone as the study group. The therapeutic effect，heart rate change，cardiac function and adverse reactions of the patients in the two groups were compared and statistically analyzed. Results the effective rate of treatment in the study group was higher than that in the control group （P<0.05）. Heart rate improvement in the study group was better than that in the control group （P<0.05）. Both left ventricular ejection fraction and left ventricular end-diastolic diameter improved better in the study group than in the control group （P<0.05）. Compared with the control group，the adverse reactions in the study group were P>0.05. Conclusion irbesartan combined with amiodarone can effectively improve the effective rate and cardiac function in patients with chronic heart failure complicated with ventricular arrhythmia.

Keywords： irbesartan; Amiodarone; Chronic heart failure; Ventricular arrhythmia

【中圖分类号】R541.6【文献标识码】A【文章编号】1672-3783（2019）12-03--01

前言

研究数据表明，全球心力衰竭患者人数约为1%-2%，对人类健康安全产生严重威胁，成为公共卫生问题。心力衰竭并非独立存在的一种疾病，往往合并多种疾病共同存在，如缺血性心肌病等。临床上跟据发作部位，将心力衰竭分为三种：左心衰、右心衰与合心衰，多数患者慢性心衰由左心衰开始[1]。近年来，人们生活方式发生改变，且老龄化社会严重，心力衰竭患者数量逐渐增多，有效治疗成为临床研究的重点。慢性心力衰竭往往合并快速心律失常，需及时给予有效治疗，避免病程延长，威胁患者生命安全[1]。本文将以我院近两年（2016年2月-2018年12月）100例患者为对象，探究厄贝沙坦联合胺碘酮治疗慢性心力衰竭合并室性心律失常的临床疗效。……